This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Vaccinations in COPD

Authoring team

Influenza vaccination

  • reduces serious illness and death in COPD patients
  • vaccines containing either killed live inactivated virus are recommended as they are more effective in elderly patients with COPD
  • population-based studies have reported a decreased risk of ischemic heart disease when they were vaccinated with influenza vaccine over many years

COVID-19 vaccination

  • SARS-CoV-2 (COVID-19) vaccination is recommended for people with COPD

Respiratory syncytial virus (RSV) vaccination

  • RSV vaccine is recommended for individuals over 60 years and/or with chronic heart or lung disease

Pneumococcal vaccination

  • the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been shown to reduce the incidence of community-acquired pneumonia in COPD patients <65 years with an FEV1 <40% predicted and in those with comorbidities (especially cardiac)
  • in adults >=65 years, the 13-valent conjugated pneumococcal vaccine (PCV13) has shown significant efficacy in reducing bacteraemia and serious invasive pneumococcal disease (1)

Reference:

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 report. 2025 [internet publication].

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.